XORTX Therapeutics Files August 2024 Report
Ticker: XRTX · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, sec-form-6k, foreign-private-issuer
TL;DR
XORTX files its monthly update, confirming 20-F reporting and CEO sign-off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on August 29, 2024, to report its activities for the month of August 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides an update on XORTX Therapeutics' regulatory reporting status and confirms their adherence to SEC requirements for foreign private issuers.
Risk Assessment
Risk Level: low — This is a routine filing confirming reporting status and not disclosing new material financial or operational information.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- August 29, 2024 (date) — Filing Date
- Allen Davidoff (person) — Chief Executive Officer
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report on the activities of XORTX Therapeutics Inc. for the month of August 2024 and to confirm its status as a foreign private issuer filing under Form 20-F.
Who signed this report on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, the Chief Executive Officer of XORTX Therapeutics Inc., signed the report.
What is the filing date of this report?
The filing date of this report is August 29, 2024.
Does XORTX Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?
XORTX Therapeutics Inc. files its annual reports under Form 20-F.
What is the company's principal business address?
The company's principal business address is Suite 2400 - 745 Thurlow Street, Vancouver, A1, V6E 0C5.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-08-29 07:00:06
Filing Documents
- f6k_082924.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-004964.txt ( ) — 15KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: August 29, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated August 29, 2024